ANNX Live signaler | Maksimer profitt med Getagraph.com

KJøP 139930 min ago

@ $5.26

Utstedt: 14 feb 2024 @ 20:48

Avkastning: -8.66%

Forrige signal: feb 14 - 15:31

Forrige signal: Selg

Avkastning: 2.24 %

Live Chart Being Loaded With Signals

Commentary (21 mai 2024 @ 22:00):

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...

Stats
Dagens volum	946 984
Gjennomsnittsvolum	1.93M
Markedsverdi	437.48M
EPS	$0 ( 2024-05-13 )
Neste inntjeningsdato	( $-0.250 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.29
ATR14	$0.0100 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Carson William H.	Buy	3 200	Common Stock
2024-04-08	Carson William H.	Buy	3 200	Common Stock
2024-02-16	Love Douglas	Buy	656 200	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	160 000	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	39 000	Common Stock

INSIDER POWER
80.76
Last 94 transactions
Buy: 9 091 580 \| Sell: 849 119

Volum Korrelasjon

Lang: 0.66 (moderate)

Kort: 0.71 (moderate)

Signal:(81.7) Neutral

Annexon, Inc. Korrelasjon

10 Mest positive korrelasjoner
HNST	0.825
VINC	0.809

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Annexon, Inc. Korrelasjon - Valuta/Råvare

-0.52
( weak negative )

0.34
( neutral )

0.00
( neutral )

0.22
( neutral )

-0.46
( neutral )

0.62
( weak )

Annexon, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-3.27M (0.00 %)
EPS:	$-1.770

FY	2023
Omsetning:	$0
Bruttogevinst:	$-3.27M (0.00 %)
EPS:	$-1.770

FY	2022
Omsetning:	$0
Bruttogevinst:	$-3.31M (0.00 %)
EPS:	$-2.53

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-7.68

Financial Reports:

No articles found.

Annexon, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.